A Randomized Phase II Multicenter, Open-Label Study Evaluating the Efficacy and Safety of IMAB362 in Combination With the EOX Regimen as First-Line Treatment of Patients With CLDN18.2-positive Adenocarcinomas of the Stomach, the Esophagus or the Gastroesophageal Junction.

Trial Profile

A Randomized Phase II Multicenter, Open-Label Study Evaluating the Efficacy and Safety of IMAB362 in Combination With the EOX Regimen as First-Line Treatment of Patients With CLDN18.2-positive Adenocarcinomas of the Stomach, the Esophagus or the Gastroesophageal Junction.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs Claudiximab (Primary) ; Capecitabine; Epirubicin; Oxaliplatin
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FAST
  • Sponsors Astellas Pharma Global Development; Ganymed Pharmaceuticals
  • Most Recent Events

    • 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium
    • 26 Oct 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018.
    • 06 Jun 2017 Results assessing tumor CLDN18.2 expression and co-expression with HER2 in gastric, gastroesophageal junction, and esophageal cancers presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top